Evidence map›Paper›PMID 40091425›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Hydrogel-Transformable Probiotic Powder for Targeted Eradication of Helicobacter pylori with Enhanced Gastric Mucosal Repair and Microbiota Preservation.

Yongkang Lai, Hanchun Shen, Shige Wang, Yongliang Ouyang, Xinyuan Zhang, Bin Hu, Xiaoyi Zhang, Guisheng Li, Lizhi Xu, Jiulong Zhao

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Living Hydrogels: Harnessing Microorganism-Material Synergy for Next-Generation Therapeutics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  8. Beyond Antibiotics: Alternative Strategies TargetingExpert reviews in molecular medicine · 2026
    Review
  9. Article
  10. Review
  11. Progress in immunotherapy forFrontiers in cellular and infection microbiology · 2026
    Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Yongkang LaiDepartment of Gastroenterology, Shanghai Institute of Pancreatic Diseases, Changhai Hospital; National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai, 200433, P. R. China.ORCID https://orcid.org/0000-0002-1493-6446
Hanchun ShenSchool of Materials and Chemistry, University of Shanghai for Science and Technology, Shanghai, 200093, P. R. China.
Shige WangSchool of Materials and Chemistry, University of Shanghai for Science and Technology, Shanghai, 200093, P. R. China.ORCID https://orcid.org/0000-0002-7639-6035
Yongliang OuyangSchool of Materials and Chemistry, University of Shanghai for Science and Technology, Shanghai, 200093, P. R. China.
Xinyuan ZhangSchool of Materials and Chemistry, University of Shanghai for Science and Technology, Shanghai, 200093, P. R. China.
Bin HuSchool of Materials and Chemistry, University of Shanghai for Science and Technology, Shanghai, 200093, P. R. China.
Xiaoyi ZhangDepartment of Mechanical Engineering, The University of Hong Kong, Hong Kong, SAR, 999077, P. R. China.
Guisheng LiSchool of Materials and Chemistry, University of Shanghai for Science and Technology, Shanghai, 200093, P. R. China.
Lizhi XuDepartment of Mechanical Engineering, The University of Hong Kong, Hong Kong, SAR, 999077, P. R. China.ORCID https://orcid.org/0000-0001-6888-0524
Jiulong ZhaoDepartment of Gastroenterology, Shanghai Institute of Pancreatic Diseases, Changhai Hospital; National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai, 200433, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lactobacillus reuteri (L. reuteri) therapies represent a potentially effective approach to eradicating Helicobacter pylori (H. pylori). However, the difficulty in bacterial viability preservation and harsh gastric environment compromises the survival and on-target delivery of L. reuteri. This study presents a novel bacterium-mediated bacterial elimination strategy using an edible L. reuteri@HTP probiotic powder for targeted bacterial elimination. The probiotic powder is obtained by grinding a lyophilized hydrogel composed of L. reuteri, hyaluronic acid (HA), tannic acid (TA), and polyvinyl alcohol (PVA). Upon contact with water, the powder quickly transforms into a hydrogel, enhancing L. reuteri's survival in the harsh gastric environment and ensuring selective release at H. pylori-infected inflammatory sites. L. reuteri targets and reduces H. pylori colonization while secreting reuterin to eliminate the bacteria. Additionally, TA's antioxidant properties help alleviate inflammation, and HA supports gastric mucosal repair. L. reuteri@HTP powder preserves the integrity of the gut microbiota, facilitating the restoration of a healthy microbiome. In particular, the probiotic powder remains stable at room temperature for at least six months, providing a promising alternative to traditional antibiotics for H. pylori treatment. This strategy combines targeted eradication, mucosal healing, and microbiome restoration, offering a new approach to treating gastric infections.

Indexed as

Gastric MucosaGastrointestinal MicrobiomeHelicobacter InfectionsHelicobacter pyloriHydrogelsLimosilactobacillus reuteriProbioticsAnimalsMicePowdersHydrogelsPowdersH. pylorihydrogelL. reuteriprobiotic powderROS‐responsive

Identifiers

PMID40091425
PMCPMC12199445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.